Elena Jachetti

Researcher (non-academic)

Fondazione IRCCS Istituto Nazionale dei Tumori
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (27)

Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer that emerges as tumors become resistant to hormone therapies or, rarely, arises de novo in treatment-naïve patients. The urgent need for effective therapies against NEPC is hampered by the limited knowledge of the biology governing this lethal disease. Based on our prior observations in the transgenic adenocarcinoma of the mouse prostate (TRAMP) spontaneous prostate cancer model, in which the genetic depletion of either mast cells (MC) or the matricellular protein osteopontin (OPN) increases NEPC frequency, we tested the hypothesis that MCs can restrain NEPC through OPN production, using in vitro co-cultures between murine or human tumor cell lines and MCs, and in vivo experiments. We unveiled a role for the intracellular isoform of OPN, so far neglected compared with the secreted isoform. Mechanistically, we unraveled that the intracellular isoform of OPN promotes TNFα production in MCs via the TLR2/TLR4-MyD88 axis, specifically triggered by the encounter with NEPC cells. We found that MC-derived TNFα, in turn, hampered the growth of NEPC. We then identified the protein syndecan-1 (SDC1) as the NEPC-specific TLR2/TLR4 ligand that triggered this pathway. Interrogating published single-cell RNA-sequencing data, we validated this mechanism in a different mouse model. Translational relevance of the results was provided by in silico analyses of available human NEPC datasets and by immunofluorescence on patient-derived adenocarcinoma and NEPC lesions. Overall, our results show that MCs actively inhibit NEPC, paving the way for innovative MC-based therapies for this fatal tumor. We also highlight SDC1 as a potential biomarker for incipient NEPC.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Background EZH2 promotes aggressive-variant prostate cancer (AVPC) progression via histone H3-Lysine-27 tri-methylation (H3K27me3). We hypothesize that epigenetic reprogramming via EZH2 inhibitors (EZH2i) improves the efficacy of chemotherapy in AVPC. Methods We studied the expression of EZH2 in clinical prostate cancer cohorts (bioinformatics). We determined the effect of EZH2i on both cellular- and cell-free-H3K27me3 levels. We measured effects of carboplatin with/without EZH2i on AVPC cell viability (IC 50 ). We studied how EZH2i modulate gene expression (RNA Seq). Results EZH2 was significantly up-regulated in AVPC vs other prostate cancer types. EZH2i reduced both cellular and cell free-H3K27me3 levels. EZH2i significantly reduced carboplatin IC 50 . EZH2i reduced the expression of DNA repair and increased the expression of pro-apoptotic genes. Article Highlights Polycomb-mediated gene silencing promotes prostate cancer progression Aggressive-variant prostate cancers (AVPCs) are characterized by increased activity of the Polycomb-Repressive Complex 2 (PRC2) Here we show that PRC2 inhibitors are scarcely effective as monotherapy in ACPC cells However the combination of PRC2 inhibitors and carboplatin is highly synergistic RNA Seq studies revealed that PRC2 inhibitors enhance carboplatin activity by modulating several key pathways, including DNA repair and apoptosis.

Year:

2024

Supplementary Figure S6. Quantification of western blot. A. Quantification of western blot reported in Fig. 3G. Western blots were validated twice. All histograms depict mean ± SD of biological replicates (represented by dots). One-way ANOVA followed by Tukey’s multiple comparison test was used for the analysis of significance between samples. P -values are reported as: *, P P P P P -value is not indicated, the comparison between groups is not statistically significant.

Year:

2024

Supplementary Figure S3. Toluidine blue for detection of MCs in mice. A. MC count reported as number of MCs/tumor area (cm2) in tumor samples from TRAMP mice with prostate intraepithelial neoplasia or adenocarcinoma (PIN/ADENO, n = 12), or TRAMP mice with NEPC ( n = 3), as well as in prostatectomies from untreated patients with Gleason Score 7 ( n = 10), Gleason Score 8 ( n =10), or showing evidence of NEPC ( n = 4). The histogram depict mean ± SD of biological replicates (represented by dots). B. Upper panels: representative images of toluidine blue staining in TRAMP, KitWsh-TRAMP, and OPN-/-TRAMP mice, or in KitWsh-TRAMP mice reconstituted with WT, OPN-/- or TNFa-/- MCs. Lower panels: representative images of toluidine blue staining in a prostate of a patient with adenocarcinoma. Scale bars indicate magnifications.

Year:

2024

Supplementary Figure S3. Toluidine blue for detection of MCs in mice. A. MC count reported as number of MCs/tumor area (cm2) in tumor samples from TRAMP mice with prostate intraepithelial neoplasia or adenocarcinoma (PIN/ADENO, n = 12), or TRAMP mice with NEPC ( n = 3), as well as in prostatectomies from untreated patients with Gleason Score 7 ( n = 10), Gleason Score 8 ( n =10), or showing evidence of NEPC ( n = 4). The histogram depict mean ± SD of biological replicates (represented by dots). B. Upper panels: representative images of toluidine blue staining in TRAMP, KitWsh-TRAMP, and OPN-/-TRAMP mice, or in KitWsh-TRAMP mice reconstituted with WT, OPN-/- or TNFa-/- MCs. Lower panels: representative images of toluidine blue staining in a prostate of a patient with adenocarcinoma. Scale bars indicate magnifications.

Year:

2024

Supplementary Figure S2. OPN evaluation in bone marrow-derived MCs. A. Separate channels of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue) of WT and OPN-/- MCs showed in Fig. 1A B. Representative images of 3 different biological replicates of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue), in WT and OPN-/- MCs. These pictures were used for the quantification reported in Fig. 1B.

Year:

2024

Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer that emerges as tumors become resistant to hormone therapies or, rarely, arises de novo in treatment-naïve patients. The urgent need for effective therapies against NEPC is hampered by the limited knowledge of the biology governing this lethal disease. Based on our prior observations in the transgenic adenocarcinoma of the mouse prostate (TRAMP) spontaneous prostate cancer model, in which the genetic depletion of either mast cells (MC) or the matricellular protein osteopontin (OPN) increases NEPC frequency, we tested the hypothesis that MCs can restrain NEPC through OPN production, using in vitro co-cultures between murine or human tumor cell lines and MCs, and in vivo experiments. We unveiled a role for the intracellular isoform of OPN, so far neglected compared with the secreted isoform. Mechanistically, we unraveled that the intracellular isoform of OPN promotes TNFα production in MCs via the TLR2/TLR4-MyD88 axis, specifically triggered by the encounter with NEPC cells. We found that MC-derived TNFα, in turn, hampered the growth of NEPC. We then identified the protein syndecan-1 (SDC1) as the NEPC-specific TLR2/TLR4 ligand that triggered this pathway. Interrogating published single-cell RNA-sequencing data, we validated this mechanism in a different mouse model. Translational relevance of the results was provided by in silico analyses of available human NEPC datasets and by immunofluorescence on patient-derived adenocarcinoma and NEPC lesions. Overall, our results show that MCs actively inhibit NEPC, paving the way for innovative MC-based therapies for this fatal tumor. We also highlight SDC1 as a potential biomarker for incipient NEPC.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (14)

Benedetto Grimaldi

Senior Researcher

Istituto Italiano di Tecnologia

ITALY
View details

Shusuke Akamatsu

Professor

Nagoya University Hospital

JAPAN
View details

Daniele Lecis

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Claudio Tripodo

-

ITALY
View details

Milena Perrone

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Elda Tagliabue

Head of Molecular Targeting Unit

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Sabina Sangaletti

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Carlo Pucillo

Full Professor

University of Udine

ITALY
View details

Sushila Rigas

Open University

UNITED KINGDOM
View details

Mario Paolo Colombo

Head of Department

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Francesco Crea

Professor (Chair) of Cancer Pharmacology

Open University

UNITED KINGDOM
View details

Roberta Sulsenti

Open University

UNITED KINGDOM
View details

Claudia Chiodoni

Senior Staff scientist

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Valeria Cancila

Assistant Professor

University of Palermo

ITALY
View details